IRIX News & Events

Iridex announced its intent to relocate the Company's headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter of intent for a new lease. The Company plans to move to the 31,000 square feet location and is expecting to generate savings of approximately $0.4 million in fiscal year 2026 and approximately $0.6 million in savings on an annualized basis thereafter. The terms of the Lease remain subject to change, and the Company cannot provide any guarantee that the Lease will be executed upon these same terms or at all.

Total revenue is expected to be between $14.6 million and $14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17%. "In 2025, we strengthened our financial position through focused cost reductions, gross margin expansion, and improved commercial efficiency, and increased probe sales," said Patrick Mercer, President and CEO of IRIDEX. "When we set and communicated our goals for 2025, we were clear about what we intended to accomplish-and in 2025 we delivered. The actions we took drove a fifth consecutive quarter of year-over-year revenue growth, reduced operating expenses, and improved adjusted EBITDA. We achieved positive cash flow in the fourth quarter of 2025, and we expect to achieve positive adjusted EBITDA for the full year 2025."

Iridex announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse technology can safely and effectively further reduce intraocular pressure, or IOP, in patients with glaucoma. The study aimed to assess the effectiveness, repeatability, and safety of retreatment in real-world clinical practice using MicroPulse TLT. Three months after retreatment, all patient groups demonstrated meaningful IOP reductions, ranging from approximately 25% to 35%, regardless of their prior response to the primary treatment. Retreatment timing varied widely across patient groups, reflecting the individualized nature of glaucoma management. On average, patients received their first retreatment as early as approximately 4 months in nonresponders and as late as more than 28 months in patients with late-attrition. Among the subset of patients who required a second retreatment, intervals ranged from about 3 months to nearly 2 years in enhancement cases.